MS. CONNOLLY: I believe we concluded it, your Honor. But the 30(b)(6) wouldn't necessarily have covered the actual transmittals that occurred, and that was also a 30(b)(6) that was taken before we realized we didn't have a complete set of these transmittal documents from the defendant, because there were communications that were ongoing when we were asking AstraZeneca, "We don't think we have all these. Can you try to find them?" They said, "Sure. We'll try to find them."

And so it was only very recently that we learned

And so it was only very recently that we learned they were not going to be able to find the detailed lists of the transmittals themselves, and, therefore, we would need these depositions, which is why this issue came up in the last two weeks of the class period.

THE COURT: All right. Anything else on these 12?

MS. CONNOLLY: That's it for those 12, your Honor.

THE COURT: All right.

I'll hear you, Counsel.

MS. HARRIS: Good morning, your Honor.

Plaintiffs have had ample opportunity to develop discovery with respect to Zoladex.

THE COURT: Well, let's go through each one of these people. This is the way I want to deal with it.

MS. HARRIS: Okay. All right. It might be helpful if I let you know the number of deponents they have